Literature DB >> 2161298

The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy.

H M Whitehead1, R Beacom, B Sheridan, A B Atkinson.   

Abstract

Cyproheptadine and bromocriptine have been reported to be therapeutic in suppressing ACTH levels in Cushing's disease and Nelson's syndrome. However, there have been only scattered reports of their effect in suppressing raised ACTH levels found in patients cured of Cushing's disease by bilateral adrenalectomy. In order to assess whether these agents could prove beneficial in such patients we studied 12 patients previously treated with bilateral adrenalectomy alone for Cushing's disease before and after 3 weeks of cyproheptadine and/or bromocroptine therapy. All had raised plasma ACTH values but no patient had evidence of a pituitary macroadenoma. Plasma ACTH and cortisol were sampled 2-hourly for 24 h. Neither drug regime led to any change in plasma levels of cortisol for 24 h after a 20 mg dose of oral hydrocortisone. Plasma ACTH (mean +/- SEM) showed a small but significant overall reduction (523 +/- 45 vs 392 +/- 34 ng/l; P less than 0.05) while on bromocriptine alone (5 mg given at 0800 and 1800 h, n = 5). When each time point was analysed individually this reduction was significant at only five out of 13 time points. At 0400 h plasma ACTH (mean +/- SEM) was 758.4 +/- 298.1 vs 380.2 +/- 166.6; 0600 h, 795 +/- 288.7 vs 477.8 +/- 191.7; 1200 h, 266.8 +/- 106.2 vs 187.0 +/- 80.3; 1400 h, 470.0 +/- 239.0 vs 302.0 +/- 135.9; 1600 h, 548.6 +/- 262.5 vs 394.2 +/- 178.5 ng/l (P less than 0.05). There was no significant change in plasma ACTH during treatment with the combination of bromocriptine and cyproheptadine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161298     DOI: 10.1111/j.1365-2265.1990.tb00855.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.

Authors:  R Pivonello; A Faggiano; F Di Salle; M Filippella; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

2.  Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.

Authors:  Ilana Shraga-Slutzky; Ilan Shimon; Ruth Weinshtein
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

3.  Role of bilateral adrenalectomy in Cushing's disease.

Authors:  G Favia; M Boscaro; F Lumachi; D F D'Amico
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

4.  Remission in Cushing disease with cabergoline.

Authors:  Raju Gopal; Tushar Bandgar; Padma Menon; Nalini Shah
Journal:  Ann Saudi Med       Date:  2008 May-Jun       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.